BioSpace News Archive

DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1 (PH1).

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors provided an operational update and released financial results for the fiscal year ended April 30, 2019.

AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced additional positive data from its proof of concept clinical trial for the reduction of cellulite.

Inscopix today announced a new research collaboration with Biogen to research and develop a new class of therapies for chronic pain.

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research [15-July-2019] ROCHESTER, N.Y. , July 15, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501c3 non-profit organization supported by Hyundai and its U.S. dealers, announces $100,000 H

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, shares the results of a new prospective clinical study of the use of ultrasound enhancing agents (UEAs) in transthoracic echocardiography reaffirming the proven safety profile of its LUMASON ultrasound enhancing agent.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) today announced that it has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer

Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create breakthrough therapies for previously untreatable diseases, today announced key leadership transitions

Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced the closing of a $121 million Series C financing.